Oxendolone Explained

Oxendolone, sold under the brand names Prostetin and Roxenone, is an antiandrogen and progestin medication which is used in Japan in the treatment of enlarged prostate.[1] [2] [3] [4] [5] However, this use is controversial due to concerns about its clinical efficacy. Oxendolone is not effective by mouth and must be given by injection into muscle.

Oxendolone is an antiandrogen, and hence is an antagonist of the androgen receptor, the biological target of androgens like testosterone and dihydrotestosterone. It is also a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. Due to its progestogenic activity, oxendolone has antigonadotropic effects. Oxendolone has no other important hormonal activity...

Oxendolone was introduced for medical use in 1981. It is used only in Japan.

Medical uses

Oxendolone is used in the treatment of benign prostatic hyperplasia (BPH) in Japan. It has been used at a dosage of 200 mg once every 2 weeks via intramuscular injection.[6] Although it is approved for the treatment of BPH in Japan, concerns have been raised about its use for this condition due to poor efficacy seen in clinical trials.

Pharmacology

Pharmacodynamics

Oxendolone binds to the androgen receptor (Ki = 320 nM) and progesterone receptor (Ki = 20 nM) and acts as a weak but clinically relevant inhibitor of 5α-reductase (= 1.4 μM).[7] [8] [9] [10] The relative binding affinity of oxendolone for the androgen receptor is 0.8 to 3.6% of that of metribolone.[11] [12] Oxendolone is not a silent antagonist of the androgen receptor but is rather predominantly antagonistic with weak agonistic activity; for this reason, it has been described as a selective androgen receptor modulator.[13] The medication has potent antigonadotropic effects via its progestogenic activity.[14] It has been found to suppress luteinizing hormone and testosterone levels to an equivalent extent as allylestrenol and chlormadinone acetate, which are two progestins that are similarly used at high doses to treat BPH.

Pharmacokinetics

The oral bioavailability of oxendolone in dogs is extremely low, 1% at most.[15] Due to its low oral bioavailability, oxendolone is administered by intramuscular injection in humans.[16] [17] [18] [19] Its elimination half-life via this route is 5.0 to 6.6 days.

Chemistry

See also: List of progestogens, Steroidal antiandrogen and List of steroidal antiandrogens.

Oxendolone, also known as 16β-ethyl-19-nortestosterone or 16β-ethylestr-4-en-17β-ol-3-one, is a synthetic estrane steroid and a derivative of testosterone and 19-nortestosterone (nandrolone).

The acetate ester of oxendolone is known as TSAA-328, while the caproate ester of oxendolone is known as TSAA-330.[20] They were never marketed.

History

Oxendolone has been marketed in Japan by Takeda since 1981.

Society and culture

Generic names

Oxendolone is the generic name of the drug and its,, and .[21] It is also known by its developmental code name TSAA-291.

Brand names

Oxendolone is or has been sold under the brand names Prostetin and Roxenone.

Availability

Oxendolone is marketed only in Japan.

Notes and References

  1. Book: Elks J . The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. 14 November 2014. Springer. 978-1-4757-2085-3. 914–.
  2. Book: William Andrew Publishing. Pharmaceutical Manufacturing Encyclopedia, 3rd Edition. 22 October 2013. Elsevier. 978-0-8155-1856-3. 2935–.
  3. Book: Negwer M, Scharnow HG . Organic-chemical drugs and their synonyms: (an international survey). 2001. Wiley-VCH. 978-3-527-30247-5. 2023.
  4. Tan MH, Li J, Xu HE, Melcher K, Yong EL . Androgen receptor: structure, role in prostate cancer and drug discovery . Acta Pharmacologica Sinica . 36 . 1 . 3–23 . January 2015 . 24909511 . 4571323 . 10.1038/aps.2014.18 .
  5. Ishizuka O, Nishizawa O, Hirao Y, Ohshima S . Evidence-based meta-analysis of pharmacotherapy for benign prostatic hypertrophy . International Journal of Urology . 9 . 11 . 607–612 . November 2002 . 12534901 . 10.1046/j.1442-2042.2002.00539.x . free .
  6. Katayama T, Umeda K, Kazama T . [Hormonal environment and antiandrogenic treatment in benign prostatic hypertrophy] . ja . Hinyokika Kiyo. Acta Urologica Japonica . 32 . 11 . 1584–1589 . November 1986 . 2435122 .
  7. Book: Mallamo JP, Juniewicz PE . New horizons in the treatment of proliferative prostatic disease . Johns WS . Annual Reports in Medicinal Chemistry . https://books.google.com/books?id=HrALiG-4t7UC&pg=PA199 . 8 September 1989. 24 . Academic Press. 978-0-08-058368-6. 199– . 10.1016/S0065-7743(08)60543-6 .
  8. Book: Annual report of Shionogi Research Laboratories. 1991. 76–77.
  9. Kirby RS, Christmas T . The potential value of 5-alpha-reductase inhibition in the treatment of bladder outflow obstruction due to benign prostatic hyperplasia. World Journal of Urology. 9. 1. 1991. 0724-4983. 10.1007/BF00184713. 38790542.
  10. Bashirelahi N, Ganesan S, Ekiko DB, Young JD, Shida K, Yamanaka H, Takahashi E . Effect of 16 beta-ethyl-17 beta-hydroxy-4-estren-3-one (TSAA-291) on the binding of promegestone (R5020) and methyltrienolone (R1881) to hyperplastic and neoplastic human prostate . Journal of Steroid Biochemistry . 25 . 3 . 367–374 . September 1986 . 2430141 . 10.1016/0022-4731(86)90249-9 .
  11. Book: Dalton J, Gao W . Androgen Receptor. 2010. 143–182. 10.1007/978-90-481-3303-1_6. Nuclear Receptors: Current Concepts and Future Challenges . Proteins and Cell Regulation. Springer. 978-90-481-3302-4.
  12. Wakeling AE, Furr BJ, Glen AT, Hughes LR . Receptor binding and biological activity of steroidal and nonsteroidal antiandrogens . Journal of Steroid Biochemistry . 15 . 355–359 . December 1981 . 7339263 . 10.1016/0022-4731(81)90297-1 .
  13. Hikichi Y, Yamaoka M, Kusaka M, Hara T . Selective androgen receptor modulator activity of a steroidal antiandrogen TSAA-291 and its cofactor recruitment profile . European Journal of Pharmacology . 765 . 322–331 . October 2015 . 26335395 . 10.1016/j.ejphar.2015.08.052 .
  14. Sudo K, Yamazaki I, Masuoka M, Nakayama R . Anti-androgen TSAA-291. IV. Effects of the anti-androgen TSAA-291 (16 beta-ethyl-17 beta-hydroxy-4-oestren-3-one) on the secretion of gonadotrophins . Acta Endocrinologica. Supplementum . 229 . 3 Supplb . 53–66 . 1979 . 294107 . 10.1530/acta.0.092S053 .
  15. Book: Iga K . Slowly Disintegrating Buccal Mucoadhesive Pain-Tablet (S-DBMP-T) and Buccal Covered=Tablet System (BCTS) . Rathbone MJ, Hadgraft J, Roberts MS . Modified-Release Drug Delivery Technology . https://books.google.com/books?id=mw9W82MLYZ8C&pg=PA368 . 7 November 2002. CRC Press. 978-0-8247-0869-6. 368–.
  16. Henkler G, Klotzbach M, Koch H, Müller W, Richter J . [Progress in the area of drug development. 15] . de . Die Pharmazie . 37 . 11 . 753–765 . November 1982 . 6131442 . [Oxendolone] has been clinically tested in Japan (weekly intramuscular injection of 200-400 mg) in prostatic hypertrophy. .
  17. Hikichi Y, Yamaoka M, Kusaka M, Hara T . Selective androgen receptor modulator activity of a steroidal antiandrogen TSAA-291 and its cofactor recruitment profile . European Journal of Pharmacology . 765 . 322–331 . October 2015 . 26335395 . 10.1016/j.ejphar.2015.08.052 . According to the clinical data of TSAA-291, the plasma level of TSAA-291 after weekly intramuscular administration at 400 mg/kg for 12 weeks is approximately 100 nM (Drug Information). .
  18. Ostri P, Swartz R, Meyhoff HH, Petersen JH, Lindgård G, Frimodt-Møller C, Andersson T, Nielsen MS . 6 . Antiandrogenic treatment of benign prostatic hyperplasia: a placebo controlled trial . Urological Research . 17 . 1 . 29–33 . 1989 . 2466359 . 10.1007/bf00261046 . Thirty patients were treated with weekly injections of oxendolone 200 mg during a 3 months' period, and 30 patients were allocated to placebo treatment. . 30551043 .
  19. Midgley I, Fowkes AG, Darragh A, Lambe R, Chasseaud LF, Taylor T . The metabolic fate of the anti-androgenic agent, oxendolone, in man . Steroids . 41 . 4 . 521–536 . April 1983 . 6419414 . 10.1016/0039-128x(83)90092-2 . After intramuscular administration of 16β-ethyl-17β-hydroxy-4-[4-14C] estren-3-one (14C-oxendolone; 300 mg) to 3 human subjects, [...] . 41224726 .
  20. Masuoka M, Masaki T, Yamazaki I, Hori T, Nakayama R . Anti-androgen TSAA-291. III. Hormonal spectra of anti-androgen TSAA-291 (16 beta-ethyl-17 beta-hydroxy-4-oestren-3-one) and its derivatives . Acta Endocrinologica. Supplementum . 229 . 36–52 . 1979 . 294106 . 10.1530/acta.0.092s036 .
  21. Web site: Oxandrolone Uses, Side Effects & Warnings . Drugs.com .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Oxendolone".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.